Brinker Capital Investments’s ADMA Biologics ADMA Stock Holding History

Brinker Capital Investments’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$147K	Sell	17,556 -3,230	-16%	-$29.4K	﹤0.01%	1832
2026 Q1	$187K	Sell	20,786 -9,429	-31%	-$149K	﹤0.01%	1880
2025 Q4	$551K	Buy	30,215 +7,891	+35%	+$133K	﹤0.01%	1556
2025 Q3	$327K	Sell	22,324 -42,263	-65%	-$724K	﹤0.01%	1725
2025 Q2	$1.18M	Buy	64,587 +26,759	+71%	+$546K	0.01%	1096
2025 Q1	$751K	Buy	+37,828	New	+$654K	0.01%	1218
2023 Q4	–	Sell	-11,152	Closed	-$39.9K	–	1650
2023 Q3	$39.9K	Sell	11,152 -2,118	-16%	-$8.15K	﹤0.01%	1599
2023 Q2	$49K	Hold	13,270	–	–	﹤0.01%	1614
2023 Q1	$43.9K	Sell	13,270 -869	-6%	-$3K	﹤0.01%	1546
2022 Q4	$54.9K	Buy	+14,139	New	+$43.6K	﹤0.01%	1330

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Brinker Capital Investments's ADMA Position: Q2 2026 in Review

Brinker Capital Investments reduced its ADMA Biologics (ADMA) stake by 16% in Q2 2026, selling an estimated $29.4K and leaving 17,556 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #1832.

Brinker Capital Investments first reported a position in ADMA in Q4 2022 and has held it in 10 quarters since. The position peaked at $1.18M in Q2 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Brinker Capital Investments held 17,556 shares of ADMA Biologics worth $147K as of Q2 2026.
Brinker Capital Investments sold 3,230 ADMA Biologics shares in Q2 2026, an estimated $29.4K.
ADMA Biologics made up ﹤0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #1832 holding.
Brinker Capital Investments first reported a position in ADMA Biologics in Q4 2022 and has held it in 10 quarters since.
Brinker Capital Investments's ADMA Biologics position peaked at $1.18M in Q2 2025.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.